HC Wainwright Lowers Cardiff Oncology Price Target to $10, Maintains Buy Rating

Analyst Robert Burns of HC Wainwright & Co. has lowered the price target for Cardiff Oncology (CRDF) to $10.00, a 44.44% decrease, while maintaining a "Buy" rating. The adjustment reflects a notable change in the stock's valuation. Historically, analyst ratings for CRDF include a "Buy" rating with a $19.00 price target from Ladenburg Thalmann and a "Hold" rating with a $3.50 price target from Jefferies.

On July 2, 2025, analyst Robert Burns of HC Wainwright & Co. lowered the price target for Cardiff Oncology (CRDF) to $10.00 USD, a significant 44.44% decrease from the previous target. Despite the reduction in the price target, Burns maintained a "Buy" rating, indicating confidence in the company's long-term prospects [2].

This adjustment marks a notable change in the stock's valuation. Historically, analyst ratings for CRDF include a "Buy" rating with a $19.00 price target from Ladenburg Thalmann and a "Hold" rating with a $3.50 price target from Jefferies [2].

The change in the price target reflects a more cautious outlook on CRDF's current valuation. Burns' decision may be influenced by various factors, including market conditions, company performance, or industry trends. Investors should closely monitor the company's earnings reports and other financial developments to assess the impact of this adjustment on their investment decisions.

For further information on Cardiff Oncology and other stock recommendations, please refer to the HC Wainwright & Co. website or contact a financial advisor [2].

References:
[1] https://www.gurufocus.com/news/3015962/auph-hc-wainwright-co-assigns-buy-rating-with-17-target-auph-stock-news
[2] https://www.marketbeat.com/ratings/by-issuer/hc-wainwright-stock-recommendations/